Florian David from the Division of Systems and Synthetic Biology and Michaela Wenzel from the Division of Molecular Bioscience have both received grants from the IngaBritt and Arne Lundberg Research Foundation.
Automated droplet generation platform for high-throughput functional drug discovery
Florian has been awarded SEK 700,000 and the funding will support the establishment of a new automated droplet generation platform for high-throughput functional drug discovery.
“The support from the IngaBritt and Arne Lundbergs Forskningsstiftelse will help us overcome a key bottleneck in our research by automating droplet generation. It will substantially increase throughput and our capacity to generate large-scale datasets in future screening campaigns,” says Florian.
The platform will be integrated with existing infrastructure, enabling large-scale testing of molecular variants in relevant cellular systems. It will generate high-quality datasets for data-driven development of future therapeutics and support a broad range of biomedical research.
AI-enabled platform for the discovery of resistance-breaking therapeutics for antimicrobial-resistant lung infections
Michaela has been awarded SEK 2,600,000 for an AI-enabled platform for the discovery of resistance-breaking therapeutics for antimicrobial-resistant lung infections (AIR).
The platform focuses not on the discovery of classical antibiotics but on antibiotic resistance breakers, compounds that restore the activity of existing antibiotics. AIR builds on strong preliminary data demonstrating complete resensitization of MDR-LRI pathogens to clinically relevant antibiotics through inhibition of adaptive stress response pathways and intrinsic permeability barriers.
“The new instrument will enable us to perform high-throughput screenings and automated mode of action assays on-site, and will support several drug discovery and characterization projects aimed at combating multiresistant pathogens. This funding gives us a great opportunity for increased collaboration and will be a valuable addition to our drug discovery capabilities at the department,” says Michaela